Combinatorial Therapy for Liver Metastatic Colon Cancer: Dendritic Cell Vaccine and Low-Dose Agonistic Anti-4-1BB Antibody Co-Stimulatory Signal

Lee, Hyunah; Park, Hae-Jung; Sohn, Hye-Jin; Kim, Jong Man; Kim, Sung Joo

doi:10.1016/j.jss.2011.03.067

Cited by 23 publications

(19 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ito and colleagues (33) and Lee and colleagues (52) examined the role of anti-CD137 administration in modulating the immune responses induced by tumor lysate–pulsed DC (TP-DC) vaccinations. Combined therapy with TP-DC plus anti-CD137 mAb resulted in lower local recurrence rates and improved survival after surgical resection of subcutaneous tumors.…”

Section: Preclinical Studies Of Cd137 Antibodymentioning

confidence: 99%

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy

Yonezawa

Dutt

Chester

et al. 2015

Clinical Cancer Research

116

111

View full text Add to dashboard Cite

In the past 5 years, immunomodulatory antibodies have revolutionized cancer immunotherapy. CD137, a member of the tumor necrosis factor receptor superfamily, represents a promising target for enhancing antitumor immune responses. CD137 helps regulate the activation of many immune cells, including CD4+ T cells, CD8+ T cells, dendritic cells, and natural killer cells. Recent studies indicate that the antitumor efficacy of therapeutic tumor-targeting antibodies can be augmented by the addition of agonistic antibodies targeting CD137. As ligation of CD137 provides a costimulatory signal in multiple immune cell subsets, combination therapy of CD137 antibody with therapeutic antibodies and/or vaccination has the potential to improve cancer treatment. Recently, clinical trials of combination therapies with agonistic anti-CD137 mAbs have been launched. In this review, we discuss the recent advances and clinical promise of agonistic anti-CD137 monoclonal antibody therapy.

show abstract

Section: Preclinical Studies Of Cd137 Antibodymentioning

confidence: 99%

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy

Yonezawa

Dutt

Chester

et al. 2015

Clinical Cancer Research

116

111

View full text Add to dashboard Cite

show abstract

“…Agonistic anti–4-1BB antibodies also had antitumor activity when given together with radiation therapy in murine breast and lung cancer models and when combined with anti–PD-1 plus radiotherapy [50,51]. Finally, targeting 4-1BB with intratumoral interferon-α therapy or DC-based vaccination also produced significant antitumor responses and/or improved survival [52,53]. …”

Section: Reviewmentioning

confidence: 99%

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

Schaer¹,

Hirschhorn-Cymerman²,

Wolchok³

2014

J Immunother Cancer

108

View full text Add to dashboard Cite

With the success of ipilimumab and promise of programmed death-1 pathway-targeted agents, the field of tumor immunotherapy is expanding rapidly. Newer targets for clinical development include select members of the tumor necrosis factor receptor (TNFR) family. Agonist antibodies to these co-stimulatory molecules target both T and B cells, modulating T-cell activation and enhancing immune responses. In vitro and in vivo preclinical data have provided the basis for continued development of 4-1BB, OX40, glucocorticoid-induced TNFR-related gene, herpes virus entry mediator, and CD27 as potential therapies for patients with cancer. In this review, we summarize the immune response to tumors, consider preclinical and early clinical data on select TNFR family members, discuss potential translational challenges and suggest possible combination therapies with the aim of inducing durable antitumor responses.

show abstract

“…Therapeutic effects of agonistic anti-4-1BB mAb are due to enhanced natural killer (NK) and CD8 + T-cell activation and IFN- γ production [140]. The current direction toward which 4-1BB-directed anticancer immunotherapy is moving is the use of anti-4-1BB mAbs in combination with other therapeutic approaches, such as antitumor necrosis factor-related apoptosis inducing ligand (TRAIL), CD40 mAbs, intratumoral delivery of IL-12 gene, DC vaccines, CTLA-4 blockade, anti-CD4 therapy, chemotherapy, and radiotherapy [4, 146, 147]. To date, one agonistic anti-4-1BB-humanized mAb BMS-663513 has been developed and the functional effects were demonstrated on human and monkey T cells and peripheral blood mononuclear cells (PBMCs), where IFN-production was enhanced compared to controls (Table 2) [148].…”

Section: The Tnf:tnfr Familymentioning

confidence: 99%

Targeting Costimulatory Molecules to Improve Antitumor Immunity

Capece

Verzella

Fischietti

et al. 2012

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

The full activation of T cells necessitates the concomitant activation of two signals, the engagement of T-cell receptor by peptide/major histocompatibility complex II and an additional signal delivered by costimulatory molecules. The best characterized costimulatory molecules belong to B7/CD28 and TNF/TNFR families and play crucial roles in the modulation of immune response and improvement of antitumor immunity. Unfortunately, tumors often generate an immunosuppressive microenvironment, where T-cell response is attenuated by the lack of costimulatory molecules on the surface of cancer cells. Thus, targeting costimulatory pathways represent an attractive therapeutic strategy to enhance the antitumor immunity in several human cancers. Here, latest therapeutic approaches targeting costimulatory molecules will be described.

show abstract

Combinatorial Therapy for Liver Metastatic Colon Cancer: Dendritic Cell Vaccine and Low-Dose Agonistic Anti-4-1BB Antibody Co-Stimulatory Signal

Cited by 23 publications

References 19 publications

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

Targeting Costimulatory Molecules to Improve Antitumor Immunity

Contact Info

Product

Resources

About